|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1001 Pennsylvania Avenue NW |
Address2 | Suite 710 |
City | Washington |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 6484-12
|
||||||||
|
6. House ID# 314020000
|
TYPE OF REPORT | 8. Year | 2023 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Samuel Marchio |
Date | 7/20/2023 4:49:40 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
ACA 1332 Waivers
Individual Market and Exchange Stabilization
Prior Authorization
Dishonest and Fair Hospital Billing
Transparency in Billing Act
Facilitating Accountability in Reimbursements Act (FAIR Act) (H.R. 3417)
Site-based Invoicing and Transparency Enhancement (SITE) Act (S.1869)
Protecting Health Care for All Patients (PATIENTS) Act of 2022 (H.R. 7634)
BCBSA of Louisiana Acquisition
Flexibility in Hospital Ownership Act
Oversight of Anti-Competitive Behavior of Non-Profit Hospitals Act
Addressing Anti-Competitive Contracting Clauses Act
Hospital Claims Form Issues
Privacy and Healthcare Cybersecurity
Social Determinants of Health (SDOH)
Behavioral Health Crisis Intervention and 9-8-8 hotline services
MAT Act
Chronic Kidney Disease Conditions of Coverage Reform
Telehealth Benefit Expansion for Workers Act of 2023 (H.R.824 )
Special Enrollment Periods
Medicaid Eligibility and Renewals
Veterans Affairs Community Care Network Program
Veterans PACT Act
Defense - Military OneSource Program; H.R. 4221 - an Act to eliminate certain health care charges for members of the Selected Reserve eligible for TRICARE Reserve Select
Insurance Navigators
Network Adequacy
Provider Directories
Provider and Nursing Licensing Issues
Inpatient Only List
Association Health Plans (CHOICE Arrangement Act (H.R. 3799)
Machine Readable Files
Cancer Moonshot Initiative
AI Use in Healthcare
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Samuel |
Marchio |
|
|
|
Adam |
Goldberg |
|
|
|
James |
Stursberg |
|
|
|
Elizabeth |
Hall |
|
|
|
Timothy |
Drumm |
|
|
|
Simone |
Myrie |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
ACA 1332 Waivers
Individual Market and Exchange Stabilization
Prior Authorization
Dishonest and Fair Hospital Billing
Transparency in Billing Act
Facilitating Accountability in Reimbursements Act (FAIR Act) (H.R. 3417)
Site-based Invoicing and Transparency Enhancement (SITE) Act (S.1869)
Protecting Health Care for All Patients (PATIENTS) Act of 2022 (H.R. 7634)
BCBSA of Louisiana Acquisition
Flexibility in Hospital Ownership Act
Oversight of Anti-Competitive Behavior of Non-Profit Hospitals Act
Addressing Anti-Competitive Contracting Clauses Act
Hospital Claims Form Issues
Privacy and Healthcare Cybersecurity
Social Determinants of Health (SDOH)
Behavioral Health Crisis Intervention and 9-8-8 hotline services
MAT Act
Chronic Kidney Disease Conditions of Coverage Reform
Telehealth Benefit Expansion for Workers Act of 2023 (H.R.824 )
Special Enrollment Periods
Medicaid Eligibility and Renewals
Veterans Affairs Community Care Network Program
Veterans PACT Act
Defense - Military OneSource Program; H.R. 4221 - an Act to eliminate certain health care charges for members of the Selected Reserve eligible for TRICARE Reserve Select
Insurance Navigators
Network Adequacy
Provider Directories
Provider and Nursing Licensing Issues
Inpatient Only List
Association Health Plans (CHOICE Arrangement Act (H.R. 3799)
Machine Readable Files
Cancer Moonshot Initiative
AI Use in Healthcare
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Samuel |
Marchio |
|
|
|
Adam |
Goldberg |
|
|
|
James |
Stursberg |
|
|
|
Elizabeth |
Hall |
|
|
|
Timothy |
Drumm |
|
|
|
Simone |
Myrie |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicare Advantage (risk adjustment, coding intensity, encounter data, dual-eligible members, star ratings, extreme and uncontrollable circumstances policy, normalization factors, stars contract consolidation)
Mental Health and Substance Use (42 CFR Part 2)
Medicaid Managed Care
Medicare Site Neutrality
Site-based Invoicing and Transparency Enhancement (SITE) Act (S.1869)
Protecting Health Care for All Patients (PATIENTS) Act of 2022 (H.R. 7634)
Medicaid Actuarial Soundness
Pharmacy Benefit Manager (PBM) Operations and Practices, Spread Pricing
Social Determinants of Health (SDOH)
Health Equity/Health Disparities
Maternal health (Medicaid postpartum coverage extension, Black Maternal Health)
Medicare Savings Program (MSP) in Medicaid
H.R. 7997, Increasing Medicare Advantage Benchmark Rates in Puerto Rico and other regions with low Medicare fee-for-service penetration and to make the Medicare Savings Program available in all jurisdictions
Medicaid funding for Puerto Rico
H.R. 2217 (Territory Federal Matching Requirement Equity Act of 2021)
H.R. 1825 (A Bill to Remove the Matching Requirement for Medicare Part D Drugs)
H.R. 1826 (Fairness in Medicare Part B Enrollment Act)
S. 3778 (Territories Medicare Prescription Drug Assistance Equity Act of 2022)
Medicare Part B penalties (H.R. 4027)
Medicare Advantage reimbursement (H.R. 4411)
Medicare Savings Program (H.R. 4410)
Medicaid Eligibility and Renewals
Medicare Advantage Supplemental Benefits
Mental Health Parity
2024 Notice of Benefit and Payment Parameters
CY2024 Medicare Advantage Advance Notice and Part D Program
Medicaid and CHIP Managed Care Access, Finance, and Quality Proposed Rule
Direct and Indirect Remuneration
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Samuel |
Marchio |
|
|
|
Adam |
Goldberg |
|
|
|
James |
Stursberg |
|
|
|
Jonathan |
Bonet-Rivera |
|
|
|
Elizabeth |
Hall |
|
|
|
Timothy |
Drumm |
|
|
|
Simone |
Myrie |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Biosimilar Red Tape Elimination Act
Biologics Competition Act
Price of prescription drugs; antitrust issues;
Affordable Prescriptions for Patients Act of 2023 (S.150)
Pharmacy Benefit Manager (PBM) operations and practices, Spread Pricing
Drug Patent Reform
Robinson-Patman Act Reform
Pharmacy Benefit Manager Transparency Act (S. 127)
PBM Transparency Language in the Restoring Hope for Mental Health and Well-Being Act of 2022 (H.R.7666)
Rebates and Rebate Pass Through
Prescription Pricing for the People Act (S. 113)
Price of Prescription Drugs
Pharmacy Benefit Manager (PBM) Operations and Practices, Spread Pricing
Pharmacy Benefit Managers; Pharmacy Benefit Manager Reform Act (S. 1339)
Transparency PRICE Act (H.R. 3281)
Protecting Health Care for All Patients (PATIENTS) Act of 2022 (H.R. 7634)
INSULIN Act of 2023 (S. 1269)
Insulin Commercial Price Cap
Protecting Patients Against PBM Abuses Act (H.R. 2880)
Pharmacy Benefits Manager Accountability Act (H.R. 2679)
Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Samuel |
Marchio |
|
|
|
James |
Stursberg |
|
|
|
Adam |
Goldberg |
|
|
|
Elizabeth |
Hall |
|
|
|
Timothy |
Drumm |
|
|
|
Simone |
Myrie |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |